Janssen has built its portfolio through a process of open and continuous innovation. This is true when it comes to designing drug development programs, pushing understanding of the biology of disease, or collaborating with partners to bring new cancer medicines to market by leveraging the company’s...
With the approval of Rybrevant, Cho stressed that it is now important to conduct research on combination therapy with immune checkpoint inhibitors for solid cancers and the combination with Yuhan’s Leclaza, Korea's 31st novel drug that treats lung cancer. A Janssen Korea official said the compan...
Effective Solutions for Drug Shortages: Market Incentives, Infrastructure, and Quality Management Lung Cancer Detection Trends Show Shift in Pandemic Aftermath COVID-19's Potential Impact on Advanced-Stage Lung Cancer Trends Dr Michael A. Choti: Integrated, Multidisciplinary Cancer Care Management Crucial ...
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer Sep 10, 2024 San Diego, CA Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantam...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for the treatment of patients with metastati...
[viii]Prostate cancer is the second most common cancer in men worldwide, behind lung cancer.3More than one million patients around the world are diagnosed with prostate cancer each year.[ix]Patients with mCRPC and HRR gene alterations, of which BRCA mutations are ...
“Legend is an innovative biotech company that has developed a differentiated CAR-T therapy, which has shown promising results in early-stage multiple myeloma trials conducted in China. We are excited to bring Janssen’s global...
Drug Profile Ibrutinib - Janssen/Pharmacyclics Alternative Names: CRA-032765; IMBRUVICA; Imbruvica; ImBurvica; JNJ-54179060; PCI-32765 Latest Information Update: 16 Aug 2024 Price : €55 * Buy Profile Adis is an information provider. We do not sell or distribute actual drugs. Final ...
The drug is a clear, colorless, sterile, preservative-free, isotonic solution supplied in single-use vials containing 10 mg (1 mg/mL) of cladribine. Each mL of cladribine contains 1 mg of the active ingredient and 9 mg (0.15 mEq) of sodium chloride as an inactive ingredient. The solution...
Fischer, P.M., et al., “CDK inhibitors in clinical development for the treatment of cancer”, Expert Opin. Investig. Drugs, vol. 12, No. 6 (2003), pp. 955-970. McLaughlin, F., et al., “The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age”, Drug Di...